• Through every step of the engagement, from strategic positioning to closing, Outcome Capital far exceeded expectations. Outcome’s team are knowledgeable advisors with unique domain expertise across the value chain. I wouldn’t look further than Outcome for any life science transaction.

    Chris Mathia CEO, Innara Health

  • I don’t know where else you would find an investment bank with such expertise. They could move from financial and strategic discussions to highly scientific, clinical discussions with ease. In the end, they brought all these perspectives to bear, developing an exceptional strategy that created value for our company.

    Herb Stern CEO, Colonary Concepts

  • Outcome Capital has demonstrated an astute and insightful understanding of our value proposal and the major companies in the cardiovascular space. They provided us with invaluable strategic advice and I can’t think of better partners to have guided us through the process.

    Alex Martin President & CEO, Coherex Medical

  • They understood our technology and business as well as anyone.

    Victor Esch, PhD President & CEO, DNAe

  • Outcome worked diligently with our executives and board to develop and communicate a strategy that was instrumental in enhancing the value of our company. Their business acumen and knowledge of our market space drove a complex transaction to a very successful close.

    Lisa Dunlea CEO, XableCath

  • Advanced Uro-Solutions engaged the services of Outcome Capital late in the process of being acquired. Outcome Capital took control of all further negotiations and masterfully increased the value of our final offering. The added value Outcome Capital was responsible for was 10 times greater than the value we invested in their services. Our only regret was in not bringing them on sooner. Arnie and Oded brought an amazing team of talented, organized and highly effective individuals. We could NOT have been more satisfied.

    John D Green, MD CEO, Advanced Uro-Solutions

  • With the assistance of Outcome’s recognized expertise in the biomedical field, GenePOC was able to devise and communicate a market-aligned strategy leading to the completion a transaction efficiently and effectively. We are very pleased with the way Outcome supported us throughout this process.

    Patrice Allibert, PhD CEO, GenePOC

  • I knew Outcome by reputation, and they were the only group I felt comfortable engaging with and trusting with this deal. What they provided exceeded my expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.

    Andrew Ferrara Chairman, Boston Healthcare Associates

  • I thank the Outcome team for driving the Verrix acquisition to completion, for protecting our interests and for an excellent job in navigating the bumps along the way. The Outcome team ran a solid competitive process that caused the market to speak toward a transaction for the benefit of both buyer and seller.

    Sami El-Saden Chairman and CEO, Verrix

  • Outcome Capital was a true partner and collaborator starting from the evaluation and sourcing phase. Their teamwork and attention to detail was perfectly accompanied by their knowledge and expertise with the industry segment. Furthermore, their diligence prep rigor was extremely useful once we got to the post term-sheet/closing phase of the transaction. I could not have survived this transaction without their help.

    Rohit Nayak CEO, Electronic Registry Systems

  • We cannot thank you enough. We appreciate your guidance, expertise, candor, and the fact that you really care. What a great way to do business.

    William Peterson Founder & Director, Propella Therapeutics

Outcome Capital recognizes that the life sciences marketplace evolves rapidly as revolutionary ideas that once held ‘future promise’ come to fruition.

From advances in personalized medicine and diagnostics to transformations in medical devices and therapeutics — not only are avenues of patient care changing but also the financial landscape and fluid interplay between life sciences sectors. The Outcome Capital Life Sciences team is dedicated to following the most recent scientific advancements as well as understanding their implications on market dynamics. The unmatched combination of scientific backgrounds and business acumen of Outcome professionals ensures they see the value of their clients’ businesses not only in today’s market but also the future potential enabling them to maximize value for their clients. Outcome Capital is a trusted partner to middle-market companies providing M&A, capital raise and advisory services in life sciences markets.

  • Pharma/Biotech
  • Diagnostics
  • Medical Devices
  • Life Science Tools and Research
  • Contract Research and Manufacturing Organizations

View Resources

Featured Transactions

Has been acquired by

The undersigned acted as strategic and financial advisor to Innara Health
Elios

$32 Million

Has Completed a Growth Equity Financing

The undersigned acted as exclusive strategic & financial advisor to ELIOS Vision, Inc.

Has Completed an Oversubscribed Growth Equity Round

The undersigned acted as exclusive strategic & financial advisor to NanoHive Medical, LLC.

Received an equity investment from

The undersigned acted as the exclusive strategic & financial advisor to Innara Health, Inc.

Has sold its business to

The undersigned acted as the exclusive strategic & financial advisor to Verrix, LLC

Has sold its business to

The undersigned acted as exclusive Strategic & financial Advisor to Boston Healthcare Associates, Inc.

Has Acquired

$120 Million

GenePOC
The undersigned acted as exclusive strategic & financial Advisor to GenePOC

Has Sold Its Business To

The undersigned acted as exclusive strategic & financial Advisor to Beryllium

Has Sold Its Business To

Exclusive Financial Advisor to ColonaryConcepts

Has Sold Its Business To

Exclusive Financial Advisor to Advanced Uro-Solutions

Has Issued 5,000,000 Shares of Series A Preferred Stock

Exclusive Financial Advisor to Predictive Therapeutics

Has Sold Its Business To

Exclusive Financial Advisor to Coherex Medical

Completed Its Debt & Equity Financing & Distribution Agreement With

Exclusive Financial Advisor to Ember Therapeutics

Has Sold Its Business To

Exclusive Financial Advisor to nanoMR

Has Completed an Option Deal and Financing Led By

Exclusive Financial Advisor to IRX Therapeutics

Has Sold Its Business To

Exclusive Financial Advisor to angiolink

$60,000,000 Series C Financing By a Group Led By

Exclusive Financial Advisor to Dicerna Pharmaceuticals

$15,000,000

Exclusive Financial Advisor to Pure Life Renal

$13,100,000 Series A1 Preferred Investment From a Group Led by

Exclusive Placement Agent for Histogenics

Has Sold Its Business To

Exclusive Financial Advisor to Bioscan

$49,000,000 Histogenics Series A Preferred Investment From a Group Co-led by

Exclusive Placement Agent for Histogenics

$5,900,000 Spirus Medical Series A Preferred Investment From a Group Co-led by

Exclusive Placement Agent for Spirus Medical

Has Sold Its Business To

Exclusive Financial Advisor to Prochon Biotech

$5,300,000 Series A Preferred Investment From

Exclusive Placement Agent for arthosurface

$13,600,000 Series B Convertible Preferred Investment From a Group Led by

Exclusive Placement Agent for angiolink

$9,000,000 Series B Preferred Investment From a Group Led by

Exclusive Placement Agent for Histogenics

Has Sold Its Business To

Exclusive Financial Advisor to Claros Diagnostics

Outcome Capital is a proud member of the Massachusetts Biotechnology Council

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278